Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease-authors' reply

Affiliations

Editorial

A B Friedman et al. Aliment Pharmacol Ther. 2018 Jul.

. 2018 Jul;48(1):98-99.

doi: 10.1111/apt.14798.

¹ Department of Gastroenterology, The Alfred Hospital, Melbourne, Vic., Australia.

No abstract available

Comment on

Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).
Friedman AB, Brown SJ, Bampton P, Barclay ML, Chung A, Macrae FA, McKenzie J, Reynolds J, Gibson PR, Hanauer SB, Sparrow MP. Friedman AB, et al. Aliment Pharmacol Ther. 2018 Apr;47(8):1092-1102. doi: 10.1111/apt.14571. Epub 2018 Feb 21. Aliment Pharmacol Ther. 2018. PMID: 29468701 Clinical Trial.
Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease.
Ansari AR, Aziz A. Ansari AR, et al. Aliment Pharmacol Ther. 2018 Jul;48(1):97-98. doi: 10.1111/apt.14687. Aliment Pharmacol Ther. 2018. PMID: 29882989 No abstract available.